Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial

Authors
Category Primary study
Year 2003
This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. There was a significant cost-effective reduction in the risk of death or myocardial infarction (MI) during the first month of extended treatment with subcutaneous dalteparin.
Epistemonikos ID: b5b2de2b4aec5da3026639b1d936bba4b51c14a3
First added on: Apr 19, 2023